[go: up one dir, main page]

CO2017001712A2 - Formulaciones de compuestos biológicos para instilación - Google Patents

Formulaciones de compuestos biológicos para instilación

Info

Publication number
CO2017001712A2
CO2017001712A2 CONC2017/0001712A CO2017001712A CO2017001712A2 CO 2017001712 A2 CO2017001712 A2 CO 2017001712A2 CO 2017001712 A CO2017001712 A CO 2017001712A CO 2017001712 A2 CO2017001712 A2 CO 2017001712A2
Authority
CO
Colombia
Prior art keywords
instillation
biological compound
compound formulations
formulations
biological
Prior art date
Application number
CONC2017/0001712A
Other languages
English (en)
Inventor
Eric A Forssen
Patrick M Hughes
David C Rupp
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CO2017001712A2 publication Critical patent/CO2017001712A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen formulaciones farmacéuticas que comprenden un derivado clostridial y un agente permeabilizante para instilación intravesical.
CONC2017/0001712A 2014-07-31 2017-02-22 Formulaciones de compuestos biológicos para instilación CO2017001712A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462031302P 2014-07-31 2014-07-31
PCT/US2015/042988 WO2016019180A1 (en) 2014-07-31 2015-07-30 Formulations of biologics for intravesical instillation

Publications (1)

Publication Number Publication Date
CO2017001712A2 true CO2017001712A2 (es) 2017-05-19

Family

ID=53801236

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0001712A CO2017001712A2 (es) 2014-07-31 2017-02-22 Formulaciones de compuestos biológicos para instilación

Country Status (17)

Country Link
US (2) US20160030570A1 (es)
EP (2) EP3174523B1 (es)
JP (3) JP6585157B2 (es)
KR (2) KR20220048046A (es)
CN (1) CN106573041A (es)
AU (2) AU2015296256A1 (es)
BR (1) BR112017001888A2 (es)
CA (1) CA2955492A1 (es)
CL (1) CL2017000244A1 (es)
CO (1) CO2017001712A2 (es)
DK (1) DK3174523T3 (es)
ES (1) ES2821731T3 (es)
IL (1) IL250086B (es)
PH (1) PH12017500178A1 (es)
RU (2) RU2020115111A (es)
SG (1) SG11201700736YA (es)
WO (1) WO2016019180A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
AU2020246080A1 (en) * 2019-03-28 2021-11-18 Gc Corporation Dental Addition Silicone Composition
RU2743805C1 (ru) * 2020-06-26 2021-02-26 Государственное бюджетное учреждение здравоохранения Свердловской области "Центр специализированных видов медицинской помощи "Уральский институт травматологии и ортопедии имени В.Д. Чаклина" (ГБУЗ СО "ЦСВМП "УИТО им. В.Д. Чаклина") Способ лечения нейрогенного мочевого пузыря
RU2751649C1 (ru) * 2020-08-24 2021-07-15 Наталья Геннадиевна Галкина Способ лечения и профилактики цистита
KR20220114183A (ko) * 2021-02-08 2022-08-17 주식회사 대웅 장기 저장이 가능한 보툴리눔 독소 동결건조 제형 조성물
WO2022214964A2 (en) * 2021-04-06 2022-10-13 Connectomica Spa. Selective connexin hemichannel blockers as therapeutic compounds and methods for treating inflammatory diseases
CH720444A2 (de) * 2023-01-20 2024-07-31 Abbvie Inc Clostridium botulinum serotyp a neurotoxin (bont/a)- sequenzvarianten

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
AU777556B2 (en) 1999-08-25 2004-10-21 Allergan, Inc. Activatable recombinant neurotoxins
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
JP4981280B2 (ja) 2005-08-23 2012-07-18 本田技研工業株式会社 燃料電池
CA2658260A1 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
EP4588519A3 (en) 2008-03-14 2025-10-15 Allergan, Inc. Immuno-based botulinum toxin serotype a activity assays
EP3067049A1 (en) * 2008-12-10 2016-09-14 Allergan, Inc. Clostridial toxin pharmaceutical compositions
LT2379104T (lt) * 2008-12-31 2018-04-10 Revance Therapeutics, Inc. Injekcinės botulino toksino vaisto formos
RU2543650C2 (ru) 2009-03-13 2015-03-10 Аллерган, Инк. Иммунологические тесты на активность эндопептидаз с измененной нацеленностью
ES2689703T3 (es) 2009-03-13 2018-11-15 Allergan, Inc. Células útiles para ensayos de actividad de serotipo A de toxina botulínica basados en la respuesta inmunológica
RU2012129557A (ru) 2009-12-16 2014-01-27 Аллерган, Инк. МОДИФИЦИРОВАННЫЕ ТОКСИНЫ Clostridial, СОДЕРЖАЩИЕ ИНТЕГРИРОВАННЫЙ САЙТ-СВЯЗЫВАЮЩИЙ ДОМЕН ПРОТЕАЗНОГО РАСЩЕПЛЕНИЯ
US10471150B2 (en) * 2010-01-20 2019-11-12 Urogen Pharma Ltd. Material and method for treating internal cavities
UA108646C2 (xx) 2010-05-20 2015-05-25 Клостридіальні токсини, що руйнуються
US20120189677A1 (en) * 2011-01-20 2012-07-26 Stephen Tonge Formulations
EP2836200B1 (en) * 2012-04-08 2020-07-15 Urogen Pharma Ltd. Reverse thermal hydrogel preparations for use in the treatment of disorders of the urothelium
RU2535115C1 (ru) * 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
US11182864B1 (en) 2015-07-13 2021-11-23 David C. Fox Non-sequential restaurant order system and method

Also Published As

Publication number Publication date
ES2821731T3 (es) 2021-04-27
AU2020250260A1 (en) 2020-11-05
JP2022081521A (ja) 2022-05-31
CA2955492A1 (en) 2016-02-04
RU2017103978A (ru) 2018-08-28
WO2016019180A1 (en) 2016-02-04
AU2015296256A1 (en) 2017-03-02
IL250086B (en) 2020-11-30
PH12017500178A1 (en) 2017-06-28
JP2017522344A (ja) 2017-08-10
RU2720991C2 (ru) 2020-05-15
RU2020115111A (ru) 2020-06-10
SG11201700736YA (en) 2017-02-27
EP3747427A1 (en) 2020-12-09
IL250086A0 (en) 2017-03-30
KR20170038030A (ko) 2017-04-05
EP3174523A1 (en) 2017-06-07
CL2017000244A1 (es) 2017-10-13
JP2020055798A (ja) 2020-04-09
US20160030570A1 (en) 2016-02-04
DK3174523T3 (da) 2020-09-28
CN106573041A (zh) 2017-04-19
US20230256097A1 (en) 2023-08-17
JP6585157B2 (ja) 2019-10-02
BR112017001888A2 (pt) 2017-11-28
KR20220048046A (ko) 2022-04-19
EP3174523B1 (en) 2020-07-01
RU2017103978A3 (es) 2019-01-24

Similar Documents

Publication Publication Date Title
CO2017001712A2 (es) Formulaciones de compuestos biológicos para instilación
CO2017001994A2 (es) Compuestos activos hacia bromodominios
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
CL2016002772A1 (es) Composiciones de insulina de rápida acción
BR112016007467A2 (pt) compostos heterocíclicos e usos dos mesmos
UY34698A (es) Combinaciones farmacéuticas que comprenden un análogo de tionucleótidos
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
MX386298B (es) Composicion farmaceutica que comprende adalimumab.
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CL2016002784A1 (es) Emulsión de agua en aceite para el cuidado de la piel
EP3340988A4 (en) ION CHANNEL-INHIBITING COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
MX2016013236A (es) Formulacion inmunosupresora.
EP3009426A4 (en) 4-ALKYNYL-IMIDAZOLE DERIVATIVE AND MEDICAMENT THEREFORE AS AN ACTIVE SUBSTANCE
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
GT201600252A (es) Derivados de naftiridinadiona
CO2017007316A2 (es) Formulación farmacéutica
IL271892B1 (en) Stable cannabinoid compositions
MX392383B (es) Metodos para tratar afecciones oculares.
ZA201900121B (en) Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same
CL2019003571A1 (es) Lipido que comprende ácido docosapentanoico. (divisional solicitud 3351-2016)